AAV for pain

Steps towards clinical translation

Andreas S Beutler, M. Reinhardt

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Recombinant adeno-associated virus (rAAV) vectors consisting of self-complementary genomes and packaged in certain capsids can target primary sensory neurons efficiently and can control neuropathic pain long term by expressing opioid or non-opioid analgesic genes. This review examines the therapeutic potential of the approach in five sections: Pain control in oncology (including a discussion of cancer centers as translational pain research environment); vector biology; safety considerations and immunological lessons learned from rAAV clinical trials of other disorders; development of intrathecal rAAV therapy in rodent models of pain; and preclinical steps towards clinical translation of rAAV for pain. In the field of analgesic drug development, clinical validation of new approaches identified in rodents is currently a critical limiting step. Small-molecule therapeutics suitable as conventional drugs to probe novel targets in clinical trials are often unavailable. In this context, gene therapy could fill an important gap in the drug development process facilitating first-into-human trials of untested targeted treatments, each instantiated as a therapeutic gene.

Original languageEnglish (US)
Pages (from-to)461-469
Number of pages9
JournalGene Therapy
Volume16
Issue number4
DOIs
StatePublished - 2009
Externally publishedYes

Fingerprint

Dependovirus
Pain
Analgesics
Rodentia
Clinical Trials
Therapeutics
Translational Medical Research
Capsid
Neuralgia
Sensory Receptor Cells
Pharmaceutical Preparations
Genetic Therapy
Opioid Analgesics
Genes
Genome
Safety
Neoplasms

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Molecular Medicine

Cite this

AAV for pain : Steps towards clinical translation. / Beutler, Andreas S; Reinhardt, M.

In: Gene Therapy, Vol. 16, No. 4, 2009, p. 461-469.

Research output: Contribution to journalArticle

Beutler, Andreas S ; Reinhardt, M. / AAV for pain : Steps towards clinical translation. In: Gene Therapy. 2009 ; Vol. 16, No. 4. pp. 461-469.
@article{d41dcf90c9bd4c268bd25b62e5445f07,
title = "AAV for pain: Steps towards clinical translation",
abstract = "Recombinant adeno-associated virus (rAAV) vectors consisting of self-complementary genomes and packaged in certain capsids can target primary sensory neurons efficiently and can control neuropathic pain long term by expressing opioid or non-opioid analgesic genes. This review examines the therapeutic potential of the approach in five sections: Pain control in oncology (including a discussion of cancer centers as translational pain research environment); vector biology; safety considerations and immunological lessons learned from rAAV clinical trials of other disorders; development of intrathecal rAAV therapy in rodent models of pain; and preclinical steps towards clinical translation of rAAV for pain. In the field of analgesic drug development, clinical validation of new approaches identified in rodents is currently a critical limiting step. Small-molecule therapeutics suitable as conventional drugs to probe novel targets in clinical trials are often unavailable. In this context, gene therapy could fill an important gap in the drug development process facilitating first-into-human trials of untested targeted treatments, each instantiated as a therapeutic gene.",
author = "Beutler, {Andreas S} and M. Reinhardt",
year = "2009",
doi = "10.1038/gt.2009.23",
language = "English (US)",
volume = "16",
pages = "461--469",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - AAV for pain

T2 - Steps towards clinical translation

AU - Beutler, Andreas S

AU - Reinhardt, M.

PY - 2009

Y1 - 2009

N2 - Recombinant adeno-associated virus (rAAV) vectors consisting of self-complementary genomes and packaged in certain capsids can target primary sensory neurons efficiently and can control neuropathic pain long term by expressing opioid or non-opioid analgesic genes. This review examines the therapeutic potential of the approach in five sections: Pain control in oncology (including a discussion of cancer centers as translational pain research environment); vector biology; safety considerations and immunological lessons learned from rAAV clinical trials of other disorders; development of intrathecal rAAV therapy in rodent models of pain; and preclinical steps towards clinical translation of rAAV for pain. In the field of analgesic drug development, clinical validation of new approaches identified in rodents is currently a critical limiting step. Small-molecule therapeutics suitable as conventional drugs to probe novel targets in clinical trials are often unavailable. In this context, gene therapy could fill an important gap in the drug development process facilitating first-into-human trials of untested targeted treatments, each instantiated as a therapeutic gene.

AB - Recombinant adeno-associated virus (rAAV) vectors consisting of self-complementary genomes and packaged in certain capsids can target primary sensory neurons efficiently and can control neuropathic pain long term by expressing opioid or non-opioid analgesic genes. This review examines the therapeutic potential of the approach in five sections: Pain control in oncology (including a discussion of cancer centers as translational pain research environment); vector biology; safety considerations and immunological lessons learned from rAAV clinical trials of other disorders; development of intrathecal rAAV therapy in rodent models of pain; and preclinical steps towards clinical translation of rAAV for pain. In the field of analgesic drug development, clinical validation of new approaches identified in rodents is currently a critical limiting step. Small-molecule therapeutics suitable as conventional drugs to probe novel targets in clinical trials are often unavailable. In this context, gene therapy could fill an important gap in the drug development process facilitating first-into-human trials of untested targeted treatments, each instantiated as a therapeutic gene.

UR - http://www.scopus.com/inward/record.url?scp=64549153993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64549153993&partnerID=8YFLogxK

U2 - 10.1038/gt.2009.23

DO - 10.1038/gt.2009.23

M3 - Article

VL - 16

SP - 461

EP - 469

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 4

ER -